Index

α_1-acid glycoprotein (AAG), binding
  drugs 394, 404–5, 422, 428
  antiprogestins 14, 34–5
acrosome
  galactosyltransferase 317–21, 355–6
  PH-20 protein 359–61
  proacrosin 318–21, 346, 356–9, 368–70
  reaction, *see* acrosome reaction
  stabilizing factor (ASF) 289
  see also sperm; zona pellucida
acrosome reaction 293, 318–21, 338–70
  calcium ions 363–4
  induction of 361–70
  mechanisms 361–2
ACTH, and RU486 39
  steroidogenesis 194–8
acyl-Coenzyme A cholesterol
  acyltransferase (ACAT) 188, 191–2
adrenal, and steroidogenesis 194–8
β-adrenoceptor agonists, pharmacokinetics
  of 424
β-adrenoceptor antagonists,
  pharmacokinetics of 421–2
albumin, and drug binding 394
aldosterone, and RU 486 14
alfentanil 405, 428
aminoglycoside antibiotics,
  pharmacokinetics of 412–14
4-aminopyrozolopyrimidine (4-APP) 182
amniotic fluid 392
amoxillin 412
ampicillin 412, 413
cAMP, and luteotrophins 183–208
anaesthetics, pharmacokinetics of 427–9
analgesics, pharmacokinetics of 427–9
anovulation 68, 81
  see also lactation; menopause; menstrual
  cycle; puberty
antibiotics, pharmacokinetics of 412–14
anticoagulants, pharmacokinetics of 420
antiemetics, pharmacokinetics of 425–7
antiepileptic drugs, pharmacokinetics
  of 416–18
antihypertensive drugs, and
  pharmacokinetics 421–3
antiprogestins 1–44
  abortion 23–5
  antiglucocorticoid activity 20–1
  binding, by plasma proteins 14, 34–5
  cellular action 15–16
  embryonic development 21–2
  enzyme inhibitors 3–8
  gonadotrophin secretion 42–4
  luteolysis 42–4
  menses induction 5–8, 28–45
  metabolism 16–20
  myometrial sensitivity 24
  nidation 21–2
  parturition 40–1
  pharmacokinetics 16–20
  prostaglandins 23
  receptor antagonists 8–45
  receptors 14
  routes of administration 20
  structures 8
  see also RU486; ZK 98.734, ZK 98.299
apoprotein, *see* HDL, LDL
arachidonic acid, *see* prostaglandins
arginine vasopressin, *see* vasopressin
arginine vasotocin, *see* vasopressin
artificial insemination 78–9
aspirin, pharmacokinetics of 421
atenolol 421, 422
azastene, *see* 3β-hydroxysteroid
  dehydrogenase enzyme inhibitors

benzodiazepines, pharmacokinetics of
  415–16
benzylpenicillin 413
B/I ratio
  and hormone heterogeneity 156–66
  and physiological state 156–66
bioassay, *see* B/I ratio
birth intervals 63–103
Brattleboro rats 243, 245
breast feeding, *see* lactation
breeding season, opioid involvement 132–7
  and steroid feedback 126–7
bupivacaine 405, 428

caffeine, pharmacokinetics of 396, 412
calcium ions
  acrosome reaction 363–4
  capacitation 345
  and luteotropic agents 183
  sperm binding to zona 349

capacitation 80–2, 285–322, 343–7
  see also sperm; zona pellucida; acrosome reaction
carbamazepine 417, 418
carnitine 291
catecholamines, and oxytocin production 241
cefacetrile 414
ceftazide 413
cefuroxime 414
cephalosporin 413
cephradine 414
cervix
  oxytocin effects on 252
  softening, antiprogestins 26–9
chloramphenicol, 414
cholesterol
  adrenal 194–8
  efflux, sperm 344
  ester hydrolysis 192–4
  esterification 191–2
  free 181
  intracellular 190–1, 194–8
  lipoprotein bound 181, 187–91
  steroid substrate 179–208
  transport 194–8
  utilization 187–91
  see also HDL; LDL
cholesterol side chain cleavage enzyme (CSCC) 188
  luteotrophins 183–207
  neurohypophyseal hormones 259
  see also cholesterol; steroid; steroidogenesis
chorionic gonadotrophin, *see* glycoprotein hormones, hCG, PMSG
cimetidine 425
clearance, of drugs 392
clorazepate 416
coitus
  fecundity 69–103
  frequency 77–8, 85–91
  oxytocin release 237–9
conception
  antificial insemination 78–9
  fecundity, 68–103
  relative to ovulation 80–5
  waiting time 70–1
  see also contraception; fertility; fecundity
contraception
  antiprogestins 2–45
  post-coital 29–31
corpus luteum
  gonadotrophin receptors 43
  progesterone production, human 180
  RU 486 43
  steroidogenesis 179–208
  see also luteolysis
cortisol, and RU 486 39
  see also glucocorticoid
cumulus 340–7
  matrix structure 342
  sperm interaction 342–7
Cushing's syndrome 13

decapacitation factors 344–5, 365–7
decidual tissue, and antiprogestins 23
desmethyldiazepam 415, 416
diabetes, in pregnancy 419
diazepam 395, 404, 405, 415, 416
dicloxacillin 413
digoxin 398
diprenorphin, *see* opioid receptors
distribution volume, of drugs 391
domains, on sperm surface 292–322, 352–61
domperidone 426
dopamine antagonists 119, 129
drug
  binding, in plasma 404–6
  fetal/maternal ratio 402–6
  pharmacokinetics 390–429
  placental transfer 398–429
  tissue distribution 402–3
dynorphins, precursors 113
  see also opioid agonists; opioid antagonists; opioid peptides

early pregnancy factor (EPF) 92–3
egg
  extracellular matrices 338–70
  lifespan 80–5
  sperm interaction 306–7, 338–70
  transport 21–2
  see also cumulus; zona pellucida
embryonic development 21–2
enalapril 423
endometriolysis, RU 486 41
endometrium
  antiprogestins and 41–2
β-endorphin 113
  see also opioid agonists; opioid antagonists; opioid peptides
enkephalins, Met- and Leu-enkephalin 112–13
  see also opioid agonists, opioid antagonists; opioid peptides
epididymal plasma, composition of 287–92
epididymis
  culture 308
  membrane remodelling of sperm 285–322
  and neurohypophyseal hormones 262
  secreted proteins 300–9

sperm maturation 285–322
epostane, *see* 3β-hydroxysteroid dehydrogenase enzyme inhibitors
equine chorionic gonadotrophin, *see* PMSG
see also glycoprotein hormones
ethosuximide 417, 418
etidocaine 395
extracellular matrix
cumulus 342–7
egg 338–70
sperm interaction with 338–70

fazadinium 429
fecundability
age 76–9, 85–91
coital frequency 77
definition 69–70
estimates 74–80
fetal loss 98
model 85–91
physiological determinants 85
fecundity
age-related 65, 76–9, 85–91
components 66–70
fetal loss 91–100
humans 61–103
male contribution 100–2
fecund wait 67, 70–4
fetal loss 98–100
fertile period
length 68, 80–5
fertility
definition 61
patterns 61–103
rates 64–103
regulating agents 2–45
fertilization 306–7, 318–21, 338–70
and sperm maturation 316–21
fetal drug elimination 406
fetal drug exposure 401–6
see also fetal/maternal drug ratio; pharmacokinetics; placental transfer
fetal loss
birth interval 67, 70, 91–100
expected number 91–3
fecundity 68, 70, 91–100
gestational age 93–7
hCG 75
maternal age 84–5
paternal age 101
fetal/maternal drug ratio 402–7
determination 402
interpretation 402–7
see also fetal drug exposure; pharmacokinetics; placental transfer
flunitrazepam 416
follicle
development, and oxytocin 249
follicle stimulating hormone, *see* FSH
follitropin, *see* FSH
FSH
microheterogeneity 147–66
and oxytocin production 240
potency of forms 162–5
physiological state and form of 162–5
see also glycoprotein hormones; hCG; PMSG; LH

galactosyltransferase (GalTase)
receptor for zona 317–21, 355–6
gametes
fertile life 80–5
see also egg; sperm
gentamycin 414
GH
heterogeneity 154–5
related hormones 147–8
glucocorticoid
receptor 11–13
see also cortisol
glycoprotein hormones
carbohydrate side chains 153–4
heterogeneity 147–66
physiological status and forms of 156–66
proteolytic cleavage in 153–4
structural relationships 149–54
subunits 149–52
see also FSH; hCG; LH; PMSG; TSH
GnRH
and carbohydrate incorporation into LH 158
and FSH immunoreactivity 163
opioid involvement in secretion of 112–37
pulse generator 123
gonadotrophin releasing hormone, *see* GnRH
gonadotrophins
RU 486 42–4
see also LH; FSH; GnRH
granulosa cells
insulin-like growth factors 186–7
luteinization 182
growth factors
and oxytocin production 240
see also insulin-like growth factors
growth hormone, *see* GH

H2 antagonists, pharmacokinetics of 425
hCG
carbohydrate side chains 154
fetal loss 75, 91–3
luteotrophin 182–3

hCG (*cont.*)
potency of forms 156–7
steroidogenesis 179–208
structure 149–54
see also FSH; glycoprotein hormones; LH; PMSG
HDL
components 189
uptake 189–90
utilization 189–90, 198–200
heparin, pharmacokinetics of 420
heterogeneity of hormone structure 147–66
and potency, *see* B/I ratio
relationship to physiological state 156–66
sources of 149–56
see also FSH; glycoprotein hormones; lactogenic hormones; LH; PMSG
hexamethonium 403
high density lipoprotein, *see* HDL
hPL
related hormones 147–8
structure 155
see also lactogenic hormones
human chorionic gonadotrophin, *see* hCG
human placental lactogen, *see* hPL
hydantoin 398
3-β-hydroxysteroid dehydrogenase enzyme inhibitors 3–8
biological activity 4–8
structure 3–4
termination of pregnancy 7–8
see also antiprogestins
hypogonadal mice, and testicular oxytocin 234

immunoassay, *see* B/I ratio
implantation, and antiprogestins 21–2
insemination, artificial 78–9
insulin
luteotrophin 186–7, 200, 205–7
in pregnancy 419
insulin-like growth factors (IGF-I and -II)
luteotrophin 186, 205–7
sources 186
see also growth factors
isoxsuprine 424

labetalol 422
labetol 395, 421
lactation
anovulation 68–9, 102
fecundity 65–103
fertility 65–103
opioid involvement in anoestrus 128–32
prolactin 129
lactational anoestrus, *see* lactation
lactogenic hormones
glycosylation of 156
heterogeneity 147–66
physiological status and forms of 165–6
structural relationships 147–8, 154–6
see also GH; placental lactogen; prolactin
LDL
components 187–8
receptors 187–9, 200–7
uptake 188
utilization 187–9, 200–7
LH
lactation and 128–32
luteotrophin 182–3, 192–208
microheterogeneity 147–66
oestrous cycle and 122–7
opioid control of 112–37
ovariectomy and 126–7
and oxytocin production 240
physiological state and form of 157–62
post-menopausal women 126
potency of forms 157–62
and presence of ram 121
puberty and 117–20
seasonal changes 132–7
steroidogenesis 179–208
see also FSH; glycoprotein hormones; hCG; PMSG
lignocaine 395
lilopristone, *see* ZK 98.734
lincomycin 414
lipoproteins *see* LDL, HDL
see also cholesterol
lithium, pharmacokinetics 414–15
liver
drug metabolism 395–6
lipoprotein secretion 182
lorezepam 397, 416
low density lipoprotein *see* LDL
luteal contraception *see* post-coital contraception
luteinizing hormone *see* LH
see also GnRH
luteolysis
and oxytocin 253–8
in primates 258
prostaglandins and 25, 253–8
in ruminants 253–8
uterus and 20, 25, 253–8
luteotrophins 179–208
actions 182–6
agent 179–208
HDL metabolism 198–200
intracellular cholesterol 187–98
LDL metabolism 200–7
steroid substrate utilization 179–209
lutropin, *see* LH

mannitol 406
mating *see* coitus
maturation *see* sperm, epididymis
mecillinam 396
membrane remodelling, *see* sperm, *see also* acrosome; capacitation
menarche, *see* puberty
menopause
  fecundity 68–9
  and LH forms 161
  sterility 66, 68
menses induction
  by antiprogestins 5–8, 6–45
menstrual cycle
  length 68, 80, 85–91
  ovulatory 68, 80–1
  short luteal phase 81
methadone 405, 428
methicillin 413
methimazole 419
metochlopramide, *see* dopamine antagonists
metoprolol 395, 421, 422
microfilaments, and steroidogenesis 195–8
mifepristone *see* RU 486
morphine *see* opiate agonists
moxalactam 413
myometrial contractions
  antiprogestins 24–7
  gap junctions 27
  neurohypophyseal hormones 252
  parturition 25–7
  sensitivity to prostaglandins 37–9
  steroid inhibitors 7–8

naloxone *see* opioid antagonists
naphthoxylactic acid 421
neurohypophyseal hormones
  actions of, female 249–58
  actions of, male 258–62
  functions 227
  in gonads 225–65
  localization 227
  structure 226–7
  see also oxytocin; vasopressin
neurophysin, *see* neurohypophyseal hormones, oxytocin, vasopressin
nidation, *see* implantation
nitrazepam 416
nordiazepam 405

oestradiol *see also* oestrogen; steroid
oestrogen
  feedback and dopaminergic involvement 120
  feedback and opioid involvement 111–37
  luteotrophin 184–6, 193, 200
  and oxytocin sensitivity, cervix, myometrium 252
  regulation of oxytocin receptor 247
oestrone *see* oestrogen
oestrous cycle
  involvement of opioids 122–8
  length of 253
  oxytocin levels in 235–8
onapristone *see* ZK 98.299
opioid agonists
  FK 33–824 120
  LH secretion 122–37
  oestrous cycle 122–8
  seasonal breeding 132–7
opioid antagonists
  LH secretion 112–37
  naloxone 112–37
  WIN 44441–3, WIN 3 118
opioid peptides 112–3
  discovery 112
  distribution 113–16
  plasma concentrations 116
opioid pharmacokinetics 428
opioid receptors
  distribution 114–16
ovary
  contraction of 249
  oxytocin in 226–58
  vasopressin in 226–58
oviduct
  motility and oxytocin 252
ovulation
  basal body temperature 83–4
  probability of conception 80–5
oxazepam 397, 415, 416
oxprenolol 405, 422
oxytocin
  actions, ovary 249–52
  and female reproductive tract 250–3
  gene expression 231–2, 236
  and gonadotrophin secretion 249
  granules 232
  levels in cycle 235–8
  levels in pregnancy 236
  localization, ovary 232
  and luteolysis 253–8
  and male reproductive tract 248, 258–62
  mating and 238
  neurophysin 230–2
  ovarian, characterization of 228–30
  and prolactin secretion 249
  prostaglandins and 253–8
  pulses 236–7
  receptors 245–9, 253–7
  secretion 239–42, 253–8
  structure 226–7
  synthesis 230–2, 239–42
  in testis 232–4

oxytocin (*cont.*)
see also neurohypophyseal hormones

pancuronium 395, 398, 429
paracetamol, pharmacokinetics of 420
parturition,
and antiprogestins 25–7, 40–1
penicillin derivatives, pharmacokinetics of 412–14
pethidine 395, 420
pH, effect on drug binding 404
PH-20, sperm protein 294, 359–61
pharmacokinetics,
antiprogestins 16–20
individual drugs 411–29
in pregnancy 390–429
principles 390–2
see also fetal/maternal drug ratio; placental transfer
phenobarbitone 417
phenylethylamine 398
phenyl ethylmalonamide 417, 418
phenytoin 395, 405, 416, 417, 418
phosophoinositides,
acrosome reaction 364
luteotrophins 183
pimozide, *see* dopamine antagonists
pivmecillinam 396, 412
placenta, comparative anatomy 399
placental lactogen,
related hormones 147–8
see also hPL; lactogenic hormones
placental metabolism, of drugs 396–7
placental transfer 390–429
fetal/maternal drug ratio 402–6
measurement 409–11
mechanisms 399–401
see also pharmacokinetics; fetal drug exposure; fetal/maternal drug ratio
PMSG
carbohydrate side chains 149–51
related hormones 147–9
structure 149–54
see also FSH; glycoprotein hormones; hCG; LH
post-coital contraception
RU 486 29–31
post-partum anoestrus, *see* lactation
povidone 418
prazosin 423
pregnancy
and antiprogestins 2–45
body fat, 394
body water 393–4
early pregnancy factor (EPF) 92
fetal loss 91–102
gastric motility 393
length, fetal loss 93–7
pharmacokinetics 390–429
see also hCG
pregnant mare serum gonadotrophin, *see* PMSG
pre-pro-opiomelanocortin 113
pre-puberty, and opioid involvement 117–20
see also puberty
primidone 417, 418
proacrosin 318–21, 346, 356–9, 368–70
progesterone
biosynthesis, inhibition 3–8
production, human 180
receptor antagonists 1–45
regulation of oxytocin receptor 247
secretion 179–208
withdrawal 1–45
see also antiprogestins; cholesterol; steroidogenesis; steroid
prolactin
heterogeneity 154–6
and lactational anoestrus 128–32
luteotrophin 184, 192–208
opioid and dopaminergic involvement 128–32
physiological states and form of 165–6
related hormones 148, 154–6
structure 155, 165–6
see also lactogenic hormones; placental lactogen
propranolol 395, 404, 405, 421, 422
propyl thiouracil 419
prostaglandins,
effects of antiprogestins 35–9
and luteolysis 253–8
myometrium 37–9
and oxytocin production 239, 241
secretion 253–8
puberty
fecundity 68–9
LH potency 158
opioid regulation of 120–2
sexual differences in 117
steroid feedback 117–22

rabbit sperm autoantigen 359
ranitidine 425
receptor,
androgen 13
antiprogestins 9–14
glucocorticoid 11–13, 16
oestrogen 13–14
oxytocin 245–8
progesterone 9–11
vasopressin 245–8
zona pellucida, sperm 338–70

ritodrine 424
RU 486, RU 38486
  and aldosterone 14
  binding, plasma proteins 9–14
  cellular action 15–16
  combination with prostaglandins 37–9
  Cushing's syndrome 13
  effects, lower mammals 20–8
  effects, primates 44
  menses induction 28–45
  metabolism 16–20
  ovulation 28
  pharmacokinetics 16–20
  plasma levels 19
  post-coital contraception 29–31
  prostaglandins 35–9
  receptors 14
  side effects 32
  structure 9–10
  suppression of hCG 35
  termination of pregnancy 31–40
  see also antiprogestins

salbutamol 424, 425
salicylate 397, 405, 421
SCP_2 181, 195
semiferous tubule, contractility 261
sexual abstinence, *see* fertility
sotalol 395, 422
sperm
  activation 80–2, 346
  addition of membrane components
  capacitation 80–2, 343–7
  in epididymis 285–322
  interaction with egg 306–7, 338–70
  lifespan 80–5
  lipids 312–16
  loss of membrane components 309–16
  membrane fluidity 295–6
  membrane remodelling 285–322
  membrane structure 282–3
  motility 346
  production, age 101
  production, oxytocin 262
  rabbit sperm autoantigen 359
  zona pellucida binding 349–70
sterility
  permanent 65–103
  see also fertility
steroid
  carrier protein, *see* SCP_2
  enzyme inhibitors 3–8
  receptor antagonists 8–45
  see also glucocorticoid; oestrogen; progesterone; testosterone
steroidogenesis 179–208
  in corpus luteum 179–208
  inhibitors 3–8
  role of cytoskeleton 195–8
  vasopressin regulation of 260
sterol carrier protein, *see* SCP_2
succinimide 398
sulfisoxasole 404
sulphonamides 405
sulprostone 37–9
  see also prostaglandins
suxamethonium 398, 429

temazepam 415
terbutaline 402, 424
termination of pregnancy, *see* antiprogestins, implantation, parturition
testis
  neurohypophyseal hormones in 248, 258–61
testosterone
  epididymal secretion 290–1
  stimulation by neurohypophyseal hormones 258–62
thalidomide 397
theophylline, pharmacokinetics of 412
thionamides 419
thiopentone 428
thyroid hormones, pharmacokinetics of 418–19
thyroid stimulating hormone, *see* TSH
trilostane, *see* 3β-hydroxysteroid dehydrogenase enzyme inhibitors
trypsin inhibitor, and sperm 354–5
TSH
  related hormones 149–52
  structure 149–52

umbilicus, blood sampling 402
uteroglobin 300
uterus
  antiprogestins 2–45
  oxytocin and 252
  prostaglandins from 253–8
  receptivity, antiprogestins 21–2
  role in luteolysis 253–8
  see also myometrial contractions

valproate 405, 417, 418
vasopressin
  actions, ovary 249–52
  in Brattleboro rats 243
  and female reproductive tract 250–2
  and gonadotrophin secretion 249
  lysine vasopressin, pigs 243
  in male 258–62

vasopressin (*cont.*)
in ovary 244
receptors 245–9
secretion 239–42
structure 226–7
synthesis 244
testicular, characterization of 242–4
see also neurohypophyseal hormones
venereal disease 69

warfarin, pharmacokinetics of 420
WIN 44441–3, WIN 3 118

ZP1, ZP2, ZP3
characteristics 348–9
in fertilization 317–19, 349–61
ZK 98.734, ZK 98.299
binding, plasma proteins 9–14
cellular action 15–16
effects, lower mammals 20–8
effects, primates 44
pharmacokinetics 16
preterm parturition 26
receptors 14
structure 9–10
see also antiprogestins; RU 486
zona pellucida 338–70
acrosome reaction 361–70
glycoproteins, *see* ZP1, ZP2, ZP3
properties 347–9
sperm binding 349–61

JAN 2 2 1990